Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Immunotherapy for Pancreatic Cancer
NCT03267173Phase 1Unknown
- Sponsor
- The First Affiliated Hospital of Harbin Medical University
- Start
- Jun 2017
- Primary completion
- Jun 2019
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in pancreatic cancer (PC), sponsored by The First Affiliated Hospital of Harbin Medical University. Primary endpoint: Number of patients with tumor response at 8 weeks. Status: unknown.
02
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03267173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03267173.